---
document_datetime: 2025-12-02 06:09:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lytgobi.html
document_name: lytgobi.html
version: success
processing_time: 0.1242841
conversion_datetime: 2025-12-27 09:11:34.66808
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lytgobi

[RSS](/en/individual-human-medicine.xml/67686)

##### Authorised

This medicine is authorised for use in the European Union

futibatinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lytgobi](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80553)
- [More information on Lytgobi](#more-information-on-lytgobi-960)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lytgobi is a cancer medicine used to treat adults with cholangiocarcinoma (biliary tract cancer or cancer of the bile ducts) when the cancer cells have an abnormal form of a receptor (target) called FGFR2 on their surface. Lytgobi is used when the cancer has spread to other parts of the body or cannot be removed by surgery and has worsened after previous treatment with at least one cancer medicine.

Lytgobi contains the active substance futibatinib.

Expand section

Collapse section

## How is Lytgobi used?

Lytgobi can only be obtained with a prescription and treatment must be started by a doctor experienced in the diagnosis and treatment of the disease. The medicine is available as tablets, to be taken by mouth once a day. Treatment can continue for as long as the patient benefits from it and side effects are manageable.

For more information about using Lytgobi, see the package leaflet or contact your doctor or pharmacist.

## How does Lytgobi work?

This medicine is a tyrosine kinase inhibitor, meaning that it blocks the activity of enzymes known as tyrosine kinases. The active substance in Lytgobi, futibatinib, blocks receptors (targets) called fibroblast growth factor receptors (FGFRs), which are found on the surface of cells and help regulate cell growth. Cancer cells with changes in the FGFR gene have an abnormal form of this protein which makes them grow uncontrollably. By blocking FGFRs, futibatinib can prevent the growth of such cancer cells.

## What benefits of Lytgobi have been shown in studies?

Lytgobi was investigated in a main study involving 103 adults with cholangiocarcinoma that had spread or that could not be removed with surgery, and who had previously received at least one systemic treatment. All patients had alterations (changes) in the FGFR2 gene. All patients in the study were given Lytgobi.

When patients were given Lytgobi, the tumour size decreased in 42% (43 out of 103) of them and the response was maintained for almost 10 months on average.

## What are the risks associated with Lytgobi?

For the full list of side effects and restrictions with Lytgobi, see the package leaflet.

The most common side effects with Lytgobi (which may affect more than 1 in 5 people) include hyperphosphataemia (high levels of phosphates in the blood), nail disorders (such as nails separating from the nail bed, poor formation of the nail or change in colour of the nails), constipation, hair loss, diarrhoea, dry mouth, tiredness, nausea (feeling sick), dry skin, increased levels of liver enzymes in the blood, abdominal (belly) pain, stomatitis (inflammation of the lining of the mouth), vomiting, hand-foot syndrome (a reaction to therapy causing redness, swelling, peeling or tenderness, mainly on the hands or feet), arthralgia (joint pain), and decreased appetite.

The most common serious side effects with Lytgobi (which may affect more than 1 in 100 people), include intestinal obstruction and migraine.

## Why is Lytgobi authorised in the EU?

At the time of approval, treatment options were limited for patients with locally advanced or metastatic cholangiocarcinoma who had previously received systemic therapy and who had FGFR2 alterations. Treatment with Lytgobi resulted in a durable response in about 40% of these patients that was maintained for almost 10 months on average, with side effects that could be managed with other medicines or dose adjustments. The medicine has been given 'conditional authorisation'. This means that the European Medicines Agency decided that the benefits of Lytgobi are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the European Medicines Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

Since Lytgobi was given conditional authorisation, at the time of authorisation the company marketing Lytgobi was required to provide data from an ongoing study on the effectiveness and safety of the medicine.

## What measures are being taken to ensure the safe and effective use of Lytgobi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lytgobi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lytgobi are continuously monitored. Suspected side effects reported with Lytgobi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lytgobi

Lytgobi received a conditional marketing authorisation valid throughout the EU on 4 July 2023.

Lytgobi : EPAR - Medicine overview

Reference Number: EMA/246662/2023

English (EN) (116.05 KB - PDF)

**First published:** 18/07/2023

[View](/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-159)

български (BG) (128.75 KB - PDF)

**First published:**

18/07/2023

[View](/bg/documents/overview/lytgobi-epar-medicine-overview_bg.pdf)

español (ES) (105.42 KB - PDF)

**First published:**

18/07/2023

[View](/es/documents/overview/lytgobi-epar-medicine-overview_es.pdf)

čeština (CS) (126.84 KB - PDF)

**First published:**

18/07/2023

[View](/cs/documents/overview/lytgobi-epar-medicine-overview_cs.pdf)

dansk (DA) (103.77 KB - PDF)

**First published:**

18/07/2023

[View](/da/documents/overview/lytgobi-epar-medicine-overview_da.pdf)

Deutsch (DE) (108.27 KB - PDF)

**First published:**

18/07/2023

[View](/de/documents/overview/lytgobi-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.09 KB - PDF)

**First published:**

18/07/2023

[View](/et/documents/overview/lytgobi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (126.65 KB - PDF)

**First published:**

18/07/2023

[View](/el/documents/overview/lytgobi-epar-medicine-overview_el.pdf)

français (FR) (106.36 KB - PDF)

**First published:**

18/07/2023

[View](/fr/documents/overview/lytgobi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (128.9 KB - PDF)

**First published:**

18/07/2023

[View](/hr/documents/overview/lytgobi-epar-medicine-overview_hr.pdf)

italiano (IT) (104.78 KB - PDF)

**First published:**

18/07/2023

[View](/it/documents/overview/lytgobi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (134.46 KB - PDF)

**First published:**

18/07/2023

[View](/lv/documents/overview/lytgobi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (125.23 KB - PDF)

**First published:**

18/07/2023

[View](/lt/documents/overview/lytgobi-epar-medicine-overview_lt.pdf)

magyar (HU) (123.58 KB - PDF)

**First published:**

18/07/2023

[View](/hu/documents/overview/lytgobi-epar-medicine-overview_hu.pdf)

Malti (MT) (128.64 KB - PDF)

**First published:**

18/07/2023

[View](/mt/documents/overview/lytgobi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (104.77 KB - PDF)

**First published:**

18/07/2023

[View](/nl/documents/overview/lytgobi-epar-medicine-overview_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

18/07/2023

[View](/pl/documents/overview/lytgobi-epar-medicine-overview_pl.pdf)

português (PT) (106.44 KB - PDF)

**First published:**

18/07/2023

[View](/pt/documents/overview/lytgobi-epar-medicine-overview_pt.pdf)

română (RO) (125.81 KB - PDF)

**First published:**

18/07/2023

[View](/ro/documents/overview/lytgobi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (127.09 KB - PDF)

**First published:**

18/07/2023

[View](/sk/documents/overview/lytgobi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (124.76 KB - PDF)

**First published:**

18/07/2023

[View](/sl/documents/overview/lytgobi-epar-medicine-overview_sl.pdf)

Suomi (FI) (102.04 KB - PDF)

**First published:**

18/07/2023

[View](/fi/documents/overview/lytgobi-epar-medicine-overview_fi.pdf)

svenska (SV) (103.36 KB - PDF)

**First published:**

18/07/2023

[View](/sv/documents/overview/lytgobi-epar-medicine-overview_sv.pdf)

Lytgobi : EPAR - Risk-management-plan

Adopted

English (EN) (744.73 KB - PDF)

**First published:** 18/07/2023

[View](/en/documents/rmp/lytgobi-epar-risk-management-plan_en.pdf)

## Product information

Lytgobi : EPAR - Product information

English (EN) (353.97 KB - PDF)

**First published:** 18/07/2023

**Last updated:** 29/10/2025

[View](/en/documents/product-information/lytgobi-epar-product-information_en.pdf)

[Other languages (25)](#file-language-dropdown-816)

български (BG) (286.99 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/bg/documents/product-information/lytgobi-epar-product-information_bg.pdf)

español (ES) (196.53 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/es/documents/product-information/lytgobi-epar-product-information_es.pdf)

čeština (CS) (259.93 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/cs/documents/product-information/lytgobi-epar-product-information_cs.pdf)

dansk (DA) (378.23 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/da/documents/product-information/lytgobi-epar-product-information_da.pdf)

Deutsch (DE) (428.5 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/de/documents/product-information/lytgobi-epar-product-information_de.pdf)

eesti keel (ET) (186.96 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/et/documents/product-information/lytgobi-epar-product-information_et.pdf)

ελληνικά (EL) (293.71 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/el/documents/product-information/lytgobi-epar-product-information_el.pdf)

français (FR) (204.11 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/fr/documents/product-information/lytgobi-epar-product-information_fr.pdf)

hrvatski (HR) (254.8 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/hr/documents/product-information/lytgobi-epar-product-information_hr.pdf)

íslenska (IS) (182.77 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/is/documents/product-information/lytgobi-epar-product-information_is.pdf)

Gaeilge (GA) (251.66 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/ga/documents/product-information/lytgobi-epar-product-information_ga.pdf)

italiano (IT) (363.88 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/it/documents/product-information/lytgobi-epar-product-information_it.pdf)

latviešu valoda (LV) (262.4 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/lv/documents/product-information/lytgobi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (392.41 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/lt/documents/product-information/lytgobi-epar-product-information_lt.pdf)

magyar (HU) (259.85 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/hu/documents/product-information/lytgobi-epar-product-information_hu.pdf)

Malti (MT) (285.14 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/mt/documents/product-information/lytgobi-epar-product-information_mt.pdf)

Nederlands (NL) (364.03 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/nl/documents/product-information/lytgobi-epar-product-information_nl.pdf)

norsk (NO) (373.37 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/no/documents/product-information/lytgobi-epar-product-information_no.pdf)

polski (PL) (271.85 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/pl/documents/product-information/lytgobi-epar-product-information_pl.pdf)

português (PT) (193.1 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/pt/documents/product-information/lytgobi-epar-product-information_pt.pdf)

română (RO) (261.34 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/ro/documents/product-information/lytgobi-epar-product-information_ro.pdf)

slovenčina (SK) (257.12 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/sk/documents/product-information/lytgobi-epar-product-information_sk.pdf)

slovenščina (SL) (251.16 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/sl/documents/product-information/lytgobi-epar-product-information_sl.pdf)

Suomi (FI) (240.87 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/fi/documents/product-information/lytgobi-epar-product-information_fi.pdf)

svenska (SV) (188.36 KB - PDF)

**First published:**

18/07/2023

**Last updated:**

29/10/2025

[View](/sv/documents/product-information/lytgobi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000282565 18/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lytgobi : EPAR - All authorised presentations

English (EN) (38.88 KB - PDF)

**First published:** 18/07/2023

[View](/en/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-380)

български (BG) (54.26 KB - PDF)

**First published:**

18/07/2023

[View](/bg/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.23 KB - PDF)

**First published:**

18/07/2023

[View](/es/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.82 KB - PDF)

**First published:**

18/07/2023

[View](/cs/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.76 KB - PDF)

**First published:**

18/07/2023

[View](/da/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (47.98 KB - PDF)

**First published:**

18/07/2023

[View](/de/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.92 KB - PDF)

**First published:**

18/07/2023

[View](/et/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.47 KB - PDF)

**First published:**

18/07/2023

[View](/el/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_el.pdf)

français (FR) (47.22 KB - PDF)

**First published:**

18/07/2023

[View](/fr/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (47.6 KB - PDF)

**First published:**

18/07/2023

[View](/hr/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.23 KB - PDF)

**First published:**

18/07/2023

[View](/is/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.03 KB - PDF)

**First published:**

18/07/2023

[View](/it/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (50.28 KB - PDF)

**First published:**

18/07/2023

[View](/lv/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.17 KB - PDF)

**First published:**

18/07/2023

[View](/lt/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.03 KB - PDF)

**First published:**

18/07/2023

[View](/hu/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (50.79 KB - PDF)

**First published:**

18/07/2023

[View](/mt/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.25 KB - PDF)

**First published:**

18/07/2023

[View](/nl/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.17 KB - PDF)

**First published:**

18/07/2023

[View](/no/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.42 KB - PDF)

**First published:**

18/07/2023

[View](/pl/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.44 KB - PDF)

**First published:**

18/07/2023

[View](/pt/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.59 KB - PDF)

**First published:**

18/07/2023

[View](/ro/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.47 KB - PDF)

**First published:**

18/07/2023

[View](/sk/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.28 KB - PDF)

**First published:**

18/07/2023

[View](/sl/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.47 KB - PDF)

**First published:**

18/07/2023

[View](/fi/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.52 KB - PDF)

**First published:**

18/07/2023

[View](/sv/documents/all-authorised-presentations/lytgobi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lytgobi Active substance Futibatinib International non-proprietary name (INN) or common name futibatinib Therapeutic area (MeSH) Cholangiocarcinoma Anatomical therapeutic chemical (ATC) code L01EN04

### Pharmacotherapeutic group

antineoplastic agents

### Therapeutic indication

Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/005627

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Taiho Pharma Netherlands B.V.

Barbara Strozzilaan 201

Opinion adopted 26/04/2023 Marketing authorisation issued 04/07/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lytgobi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.79 KB - PDF)

**First published:** 29/10/2025

[View](/en/documents/procedural-steps-after/lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lytgobi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (152.61 KB - PDF)

**First published:** 19/10/2023

**Last updated:** 29/10/2025

[View](/en/documents/procedural-steps-after/lytgobi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Lytgobi : Orphan designation withdrawal assessment report (initial-authorisation)

Adopted

Reference Number: EMA/OD/0000122904

English (EN) (310.07 KB - PDF)

**First published:** 18/07/2023

[View](/en/documents/orphan-maintenance-report/lytgobi-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Lytgobi : EPAR - Public assessment report

Adopted

Reference Number: EMA/218116/2023

English (EN) (3.41 MB - PDF)

**First published:** 18/07/2023

[View](/en/documents/assessment-report/lytgobi-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Lytgobi

Adopted

Reference Number: EMA/CHMP/169349/2023

English (EN) (147.33 KB - PDF)

**First published:** 26/04/2023

[View](/en/documents/smop-initial/chmp-summary-opinion-lytgobi_en.pdf)

#### News on Lytgobi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-26-april-2023) 26/04/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Lytgobi : EPAR - Product information - tracked changes

English (EN) (82.54 KB - DOCX)

**First published:** 29/10/2025

[View](/en/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_en.docx)

[Other languages (25)](#file-language-dropdown-975)

български (BG) (95.33 KB - DOCX)

**First published:**

29/10/2025

[View](/bg/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_bg.docx)

español (ES) (89.67 KB - DOCX)

**First published:**

29/10/2025

[View](/es/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_es.docx)

čeština (CS) (90 KB - DOCX)

**First published:**

29/10/2025

[View](/cs/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (77.67 KB - DOCX)

**First published:**

29/10/2025

[View](/da/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (81.9 KB - DOCX)

**First published:**

29/10/2025

[View](/de/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (86.78 KB - DOCX)

**First published:**

29/10/2025

[View](/et/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (99.7 KB - DOCX)

**First published:**

29/10/2025

[View](/el/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_el.docx)

français (FR) (85.67 KB - DOCX)

**First published:**

29/10/2025

[View](/fr/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (89.64 KB - DOCX)

**First published:**

29/10/2025

[View](/hr/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (87.09 KB - DOCX)

**First published:**

29/10/2025

[View](/is/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_is.docx)

Gaeilge (GA) (88.48 KB - DOCX)

**First published:**

29/10/2025

[View](/ga/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_ga.docx)

italiano (IT) (88.65 KB - DOCX)

**First published:**

29/10/2025

[View](/it/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (92.88 KB - DOCX)

**First published:**

29/10/2025

[View](/lv/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (77.9 KB - DOCX)

**First published:**

29/10/2025

[View](/lt/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (85.05 KB - DOCX)

**First published:**

29/10/2025

[View](/hu/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (89.27 KB - DOCX)

**First published:**

29/10/2025

[View](/mt/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (73.87 KB - DOCX)

**First published:**

29/10/2025

[View](/nl/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (66.83 KB - DOCX)

**First published:**

29/10/2025

[View](/no/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_no.docx)

polski (PL) (91.61 KB - DOCX)

**First published:**

29/10/2025

[View](/pl/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_pl.docx)

português (PT) (88.96 KB - DOCX)

**First published:**

29/10/2025

[View](/pt/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_pt.docx)

română (RO) (82.95 KB - DOCX)

**First published:**

29/10/2025

[View](/ro/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (90.18 KB - DOCX)

**First published:**

29/10/2025

[View](/sk/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (89.06 KB - DOCX)

**First published:**

29/10/2025

[View](/sl/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (85.32 KB - DOCX)

**First published:**

29/10/2025

[View](/fi/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (87.62 KB - DOCX)

**First published:**

29/10/2025

[View](/sv/documents/product-information-tracked-changes/lytgobi-epar-product-information-tracked-changes_sv.docx)

#### More information on Lytgobi

This product is no longer an orphan medicine. It was originally designated an [orphan medicine EU/3/19/2146](/en/medicines/human/orphan-designations/eu-3-19-2146) on 01 April 2019. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in May 2023 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 29/10/2025

## Share this page

[Back to top](#main-content)